BRL-15572

BRL-15572
(IUPAC) ime
	3-(4-(4-chlorophenyl)piperazin-1-yl)-1,1-diphenyl-2-propanol
Klinički podaci
Identifikatori
CAS broj	193611-72-2
ATC kod	nije dodeljen
PubChem	3654103
ChEMBL	CHEMBL534232
Hemijski podaci
Formula	C25H27ClN2O
Mol. masa	406.947 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C25H27ClN2O/c26-22-12-7-13-23(18-22)28-16-14-27(15-17-28)19-24(29)25(20-8-3-1-4-9-20)21-10-5-2-6-11-21/h1-13,18,24-25,29H,14-17,19H2 ; Key: QJHCTHPYUOXOGM-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

BRL-15,572 je lek koji deluje selektivni antagonist serotoninskog receptorskog tipa 5-HT_1D, koji je oko 60x selektivniji u odnosu na srodne receptore.

5-HT_1D receptor ima veoma sličnu farmakologiju sa blisko srodnim 5-HT_1B receptorom, i većina starijih liganda tih receptora se vezuje za ova tipa sa aproksimativno jednakim afinitetom. Razvoj jedinjenja kao što je BRL-15572, koja imaju sposobnost selektivnog blokiranja 5-HT_1D tipa, su znatno unapredila oruđa za istraživanje funkcije tog serotoninskog receptora.^[4]^[5] Jedna od otkrivenih funkcija 5-HT_1D receptora je njegova uloga u modulaciji otpuštanja neurotransmitera glutamata u mozgu,^[6] kao i funkcije u regulaciji cerebralnog krvnog pritiska koje su važne u patogenezi migrenskih glavobolja.^[7]

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Göthert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN. SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Archives of Pharmacology. 1997 Sep;356(3):312-20. PMID 9303567
↑ Schlicker E, Fink K, Molderings GJ, Price GW, Duckworth M, Gaster L, Middlemiss DN, Zentner J, Likungu J, Göthert M. Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Archives of Pharmacology. 1997 Sep;356(3):321-7. PMID 9303568
↑ Marcoli M, Maura G, Munari C, Ruelle A, Raiteri M. Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions. British Journal of Pharmacology. 1999 Feb;126(3):607-12. PMID 10188970
↑ Goadsby PJ, Classey JD. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. PMID 14614913

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Göthert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN. SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Archives of Pharmacology. 1997 Sep;356(3):312-20. PMID 9303567

[5] Schlicker E, Fink K, Molderings GJ, Price GW, Duckworth M, Gaster L, Middlemiss DN, Zentner J, Likungu J, Göthert M. Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Archives of Pharmacology. 1997 Sep;356(3):321-7. PMID 9303568

[6] Marcoli M, Maura G, Munari C, Ruelle A, Raiteri M. Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions. British Journal of Pharmacology. 1999 Feb;126(3):607-12. PMID 10188970

[7] Goadsby PJ, Classey JD. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122(2):491-8. PMID 14614913

[1]

[2]

[3]

[4]

[5]

[6]

[7]